These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Growth in children with nephrotic syndrome.
    Author: Tsau YK, Chen CH, Lee PI.
    Journal: Taiwan Yi Xue Hui Za Zhi; 1989 Sep; 88(9):900-6. PubMed ID: 2621431.
    Abstract:
    To assess the long-term growth status and the effects of steroid therapy on the linear growth of nephrotic children, growth patterns were analyzed in 52 patients who had been followed for 2 to 12 (5.51 +/- 2.82) years. They were divided into 2 groups: (1) Group A had less favorable clinical courses, this included 29 children with frequent relapsing, steroid-dependent, and steroid-resistant nephrotic syndromes; (2) Group B, consisting of 23 nephrotic children with occasional or no relapse. When assessed by a growth velocity index (GVI) and a change in standard deviation score of height (delta SD score), 24 patients (46%) were found to have growth impairment; of these, 21 (88%) belonged to Group A. The mean adult height of 6 Group A patients was subnormal when compared to normal adults, while the value for 6 Group B patients was normal. Based on covariance analysis, steroid usage of more than 6 months per year with a dose higher than 0.2 mg/kg/day (and/or 0.4 mg/kg/48h) was found to be the major determinant on the growth pattern of nephrotic children. In conclusion, high-dose prednisolone therapy should be administered no more than 6 months per year if normal growth and adult height are desired.
    [Abstract] [Full Text] [Related] [New Search]